Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous versus intermittent vancomycin infusion in pediatric intensive care patients
IRCT20120415009475N12Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2022
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vancomycin in Staphylococcus aureus infection (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Vancomycin area under the curve. Started Aug 2022; status: completed.
02
Drugs
vancomycin
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on IRCT20120415009475N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120415009475N12.